Compare Gilead Sciences, Inc. (GILD) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Tilray Brands Inc — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Tilray Brands Inc trades at $4.77 (market cap $601.34M). The key difference: Gilead Sciences, Inc. is far larger — about 274.4× Tilray Brands Inc's market cap, and Gilead Sciences, Inc. pays a 2.47% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| GILD | TLRY | |
|---|---|---|
Market Cap | $164.99B | $601.34M |
Sector | Health | Health |
52-Week High | $155.80 | $21.00 |
52-Week Low | $110.56 | $3.88 |
Enterprise Value | $188.06B | $768.47M |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLRY trades at $4.57, up 2.93% with a bullish technical signal, though recent earnings misses and negative profitability metrics highlight fundamental challenges. The company reported record fiscal 2026 revenue of $915 million but continues to post significant net losses. Analyst sentiment is mixed with 25% buy ratings, while technical indicators show RSI near overbought levels with key support at $4.
Outlook remains cautious due to persistent losses and high valuation multiples, though revenue growth and diversification into beverages offer potential upside. Key risks include execution challenges, cannabis regulatory uncertainty, and competitive pressures in the consumer goods space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
